Federal contractor profile
Regeneron Pharmaceuticals: Federal Contracts, Agencies & Awards
Data through 2026-09-28 · FY2026 to date
- Obligations, FY2026 to date
- $279M
- Contract awards
- 3
- Average award size
- $93.1M
| Item | Obligations |
|---|---|
| FY21 | $5.6B |
| FY22 | $494K |
| FY23 | $326M |
| FY24 | $0 |
| FY25 | -$332M |
| FY26 | $279M |
Regeneron Pharmaceuticals won $279M in FY2026 to date.
Regeneron Pharmaceuticals has $279M in federal contract obligations in FY2026 to date. Regeneron Pharmaceuticals received 3 awards this fiscal year, producing an average award size of $93.1M. Recent fiscal-year obligations include $5.6B in FY21, $494K in FY22, and $326M in FY23, with $279M recorded in FY26 to date. Large individual awards drive the current-year total rather than many small purchases, and the award count and average award size are the clearest signals of Regeneron Pharmaceuticals’ federal footprint for the period shown. Buyers and competitors should note the concentration of obligations into a small number of awards when assessing Regeneron Pharmaceuticals’ role on government programs this fiscal year.
How concentrated are Regeneron Pharmaceuticals' FY2026 obligations?
Regeneron Pharmaceuticals has $279M of obligations in FY2026 to date across 3 awards. The average award size is $93.1M, which indicates concentration in relatively large awards rather than many small ones. A small award count with a high average award size means a few contracts account for most of the year-to-date total.
How has Regeneron Pharmaceuticals performed across recent fiscal years?
Regeneron Pharmaceuticals recorded $5.6B in FY21, $494K in FY22, and $326M in FY23. FY26 shows $279M to date. These figures show that federal obligations have varied materially from year to year.
| Rank | Award | Award Amount | Awarding Agency | Ends |
|---|---|---|---|---|
| 1 | HHSO100201700016C | $974M | Department of Health and Human Services | 2031-09-29 |
| 2 | HHSO100201700020C | $279M | Department of Health and Human Services | 2027-09-25 |
| 3 | HHSO100201600023C | $8.6M | Department of Health and Human Services | 2022-09-30 |
| Award | Awarding Agency | Award Value | Ends |
|---|---|---|---|
| HHSO100201700020C | Department of Health and Human Services | $279M | 2027-09-25 |
| Detail | Registration |
|---|---|
| Unique Entity ID (UEI) | N3F9MH7E6HD6 |
| Headquarters | Tarrytown, NY |
| Business types | Category business; Corporate entity not tax exempt; Manufacturer of goods; Other than small business; Special designations; Us owned business |
This is the free layer.
GovHub customers get the live version, filters, exports, and AI proposal drafting on top of this data.
No credit card required · 14-day free trial
Frequently asked questions
How much does Regeneron Pharmaceuticals make from federal contracts?
Regeneron Pharmaceuticals has $279M in federal contract obligations in FY2026 to date. The company received 3 awards this fiscal year, and the average award size is $93.1M. Historical fiscal-year totals include $5.6B in FY21, $494K in FY22, and $326M in FY23.
Which agencies buy from Regeneron Pharmaceuticals?
The data provided does not list specific agencies by name. The available figures report $279M in FY2026 obligations, 3 awards, and an average award size of $93.1M.
What does Regeneron Pharmaceuticals sell to the government?
The data provided does not list product or service descriptions for Regeneron Pharmaceuticals’ awards. Available figures show $279M in FY2026 obligations, 3 awards, and an average award size of $93.1M.
Which Regeneron Pharmaceuticals contracts are expiring soon?
The data provided does not include expiration dates or an expiring-contract table for Regeneron Pharmaceuticals’ contracts. Available figures report $279M in FY2026 obligations, 3 awards, and an average award size of $93.1M.
Found your market? GovHub writes the proposal.
Turn this market intelligence into a submitted, compliant federal proposal, faster.
No credit card required · 14-day free trial